Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Stem Cell Research

Free Subscription Articles published in Leuk Lymphoma Retrieve available abstracts of 27 articles: HTML format

Single Articles

August 2025
1. CHUMNUMSIRIWATH P, Vittayawacharin P, Pinter-Brown L, Brem EA, et al
   Lite-BEAM expands autologous stem cell transplantation access for older or unfit patients with lymphoma.
   Leuk Lymphoma. 2025 Aug 21:1-5. doi: 10.1080/10428194.2025.2547985.
   PubMed    
   
   
   
2. TOLU SS, Gribbin C, Chen Z, Seshadri MR, et al
   Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.
   Leuk Lymphoma. 2025 Aug 14:1-11. doi: 10.1080/10428194.2025.2540437.
   PubMed     Abstract available
   
   
   
3. GO AE, Feliciano EJG, Ho FDV, Dee EC, et al
   Hematopoietic stem cell Transplants in the Philippines: barriers to accessibility.
   Leuk Lymphoma. 2025 Aug 9:1-3. doi: 10.1080/10428194.2025.2544076.
   PubMed    
   
   
   July 2025
4. ANDREADIS C, Bobek O, Hsi ED, Fenske TS, et al
   Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup doub
   Leuk Lymphoma. 2025 Jul 9:1-10. doi: 10.1080/10428194.2025.2525982.
   PubMed     Abstract available
   
   
   
5. ODSTRCIL BOBILLO MS, McClune B, Couriel DR
   Access barriers to hematopoietic stem cell transplantation and CAR T-cells in US.
   Leuk Lymphoma. 2025 Jul 6:1-11. doi: 10.1080/10428194.2025.2513003.
   PubMed     Abstract available
   
   
   
6. GULLAKSEN SE, Omsland M, Brevik M, Letzner J, et al
   CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors.
   Leuk Lymphoma. 2025;66:1211-1220.
   PubMed     Abstract available
   
   
   June 2025
7. KOYABU S, Onaka T, Imada K
   Ponatinib may make allogeneic hematopoietic stem cell transplantation unnecessary for CML-BC under specific conditions, such as de novo cases: a case series of de novo CML-BC treated with ponatinib and no transplantation.
   Leuk Lymphoma. 2025 Jun 25:1-4. doi: 10.1080/10428194.2025.2521646.
   PubMed    
   
   
   
8. RATHJE K, Kroger N
   Optimal timing of allogeneic hematopoietic stem cell transplant in MDS.
   Leuk Lymphoma. 2025 Jun 19:1-13. doi: 10.1080/10428194.2025.2514662.
   PubMed     Abstract available
   
   
   
9. MEIRELES AM, Oliveira Rodrigues Amarante ACD, Marques Catita BMC, Abilheira Monjardino MTPB, et al
   Effects of fludarabine dosage on transplant-related outcomes in hematopoietic stem cell transplantation.
   Leuk Lymphoma. 2025 Jun 11:1-5. doi: 10.1080/10428194.2025.2509701.
   PubMed    
   
   
   May 2025
10. THORDARDOTTIR TH, Rodenbach RA, Brauer M, Hall AC, et al
    'A perfect match': how hematologists discuss donor options and risks with black and white patients considering allogeneic stem cell transplant.
    Leuk Lymphoma. 2025 May 7:1-10. doi: 10.1080/10428194.2025.2500625.
    PubMed     Abstract available
    
    
    
11. RAMACHANDRA N, Vegivinti CTR, Sahu S, Sanawar R, et al
    Transforming growth factor beta receptor type I (TGF-betaRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS.
    Leuk Lymphoma. 2025;66:920-929.
    PubMed     Abstract available
    
    
    April 2025
12. GOSHO K, Sadato D, Kato S, Toya T, et al
    Diamond-Blackfan anemia syndrome in an adult with RPS19 and DDX41 variants successfully treated with allogeneic stem cell transplantation: a case report.
    Leuk Lymphoma. 2025 Apr 2:1-4. doi: 10.1080/10428194.2025.2486432.
    PubMed    
    
    
    March 2025
13. BISCHOF L, Ussmann J, Platzbecker U, Jentzsch M, et al
    Allogeneic stem cell transplantation for MDS-clinical issues, choosing preparative regimens and outcome.
    Leuk Lymphoma. 2025 Mar 12:1-14. doi: 10.1080/10428194.2025.2476652.
    PubMed     Abstract available
    
    
    
14. TUCCI A, Re A, Pagani C, Marcheselli L, et al
    A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study.
    Leuk Lymphoma. 2025 Mar 8:1-9. doi: 10.1080/10428194.2025.2471499.
    PubMed     Abstract available
    
    
    February 2025
15. SUN Y, Liu N, Liu Y, Deng J, et al
    Isolated CNS B lymphoid/myeloid bilineage relapse following allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with KMT2A::MLLT1 rearrangement.
    Leuk Lymphoma. 2025 Feb 10:1-4. doi: 10.1080/10428194.2025.2460046.
    PubMed    
    
    
    December 2024
16. SHUMILOV E, Levien L, Mazzeo P, Jung W, et al
    Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning.
    Leuk Lymphoma. 2024 Dec 11:1-12. doi: 10.1080/10428194.2024.2438805.
    PubMed     Abstract available
    
    
    
17. PAISIOU A, OIkonomopoulou C, Pavlidis D, Ampatzidou M, et al
    CDKN2A/B deletion as an independent negative prognostic factor for allogeneic hematopoietic stem cell transplantation in childhood B cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Dec 1:1-4. doi: 10.1080/10428194.2024.2434177.
    PubMed    
    
    
    November 2024
18. LECORNEC N, Duchmann M, Itzykson R
    Single-cell sequencing applications in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 4:1-15. doi: 10.1080/10428194.2024.2422833.
    PubMed     Abstract available
    
    
    October 2024
19. DEHGHANI SS, Wang Y, Ramesh KH, Cooper D, et al
    Atypical chronic myeloid leukemia (CML) with ETV6-ABL1 mutation managed successfully with a third-generation TKI and hematopoietic stem cell transplant.
    Leuk Lymphoma. 2024 Oct 18:1-3. doi: 10.1080/10428194.2024.2403666.
    PubMed    
    
    
    August 2024
20. JEANSELME P, Tavitian S, Lapierre L, Vergez F, et al
    Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature.
    Leuk Lymphoma. 2024 Aug 14:1-6. doi: 10.1080/10428194.2024.2390572.
    PubMed     Abstract available
    
    
    July 2024
21. DALAL P, Dalal J
    PTCy-ATG mutually exclusive or additive? Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia.
    Leuk Lymphoma. 2024 Jul 31:1-2. doi: 10.1080/10428194.2024.2379976.
    PubMed    
    
    
    
22. TARANTINI F, Cumbo C, Anelli L, Zagaria A, et al
    Venetoclax-based treatment in acute myeloid leukemia: an unexpected bonus on the path to allogeneic hematopoietic stem cell transplant?
    Leuk Lymphoma. 2024 Jul 23:1-12. doi: 10.1080/10428194.2024.2381649.
    PubMed     Abstract available
    
    
    
23. HU M, Li J, Hu T, Zhang Z, et al
    Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia.
    Leuk Lymphoma. 2024 Jul 7:1-10. doi: 10.1080/10428194.2024.2376179.
    PubMed     Abstract available
    
    
    
24. STEWART C, Owen C, Chua N, Peters A, et al
    Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphoma.
    Leuk Lymphoma. 2024 Jul 5:1-4. doi: 10.1080/10428194.2024.2373323.
    PubMed    
    
    
    June 2024
25. JIANG J, Sigmund AM, Zhao Q, Elder P, et al
    Impact of chronic graft-versus-host disease on non-relapse mortality and survival.
    Leuk Lymphoma. 2024 Jun 12:1-8. doi: 10.1080/10428194.2024.2365910.
    PubMed     Abstract available
    
    
    May 2024
26. NAGAYAMA T, Fujiwara SI, Tominaga R, Yokoyama D, et al
    Association of the pre-transplant CD4/CD8 ratio with the prognosis following allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2024 May 20:1-7. doi: 10.1080/10428194.2024.2352614.
    PubMed     Abstract available
    
    
    
27. VON DEM BORNE PA, Kemps-Mols BM, de Wreede LC, van Beek AA, et al
    The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide.
    Leuk Lymphoma. 2024 May 6:1-11. doi: 10.1080/10428194.2024.2344060.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Stem Cell Research is free of charge.